NuVasive (NASDAQ:NUVA) & INVO Bioscience (NASDAQ:INVO) Financial Analysis

NuVasive (NASDAQ:NUVAGet Rating) and INVO Bioscience (NASDAQ:INVOGet Rating) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for NuVasive and INVO Bioscience, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NuVasive 1 4 6 0 2.45
INVO Bioscience 0 1 2 0 2.67

NuVasive presently has a consensus target price of $63.78, suggesting a potential upside of 29.50%. INVO Bioscience has a consensus target price of $2.50, suggesting a potential upside of 214.66%. Given INVO Bioscience’s stronger consensus rating and higher possible upside, analysts clearly believe INVO Bioscience is more favorable than NuVasive.

Institutional and Insider Ownership

21.7% of INVO Bioscience shares are held by institutional investors. 0.5% of NuVasive shares are held by company insiders. Comparatively, 7.6% of INVO Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

NuVasive has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, INVO Bioscience has a beta of -0.38, meaning that its share price is 138% less volatile than the S&P 500.


This table compares NuVasive and INVO Bioscience’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NuVasive -3.23% 11.85% 4.51%
INVO Bioscience -191.70% -137.40% -72.72%

Earnings & Valuation

This table compares NuVasive and INVO Bioscience’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NuVasive $1.14 billion 2.25 -$64.09 million ($0.75) -65.67
INVO Bioscience $4.16 million 2.31 -$6.66 million N/A N/A

INVO Bioscience has lower revenue, but higher earnings than NuVasive.

About NuVasive (Get Rating)

NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary implant device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California.

About INVO Bioscience (Get Rating)

INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. Its flagship product is the INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.

Want More Great Investing Ideas?

Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with's FREE daily email newsletter.